Medivir AB (publ) (OTCMKTS:MVRBF) shot up 10% during trading on Monday . The stock traded as high as $2.20 and last traded at $2.20, 300 shares changed hands during mid-day trading. A decline of 90% from the average session volume of 3,030 shares. The stock had previously closed at $2.00.

Separately, HC Wainwright began coverage on Medivir AB (publ) in a report on Tuesday, June 25th. They issued a “buy” rating for the company.

The company’s fifty day moving average is $2.00.

Medivir AB (publ) Company Profile (OTCMKTS:MVRBF)

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma; and Birinapant that is in phase II clinical trial for treating colorectal cancer.

Featured Article: Does the Dogs of the Dow strategy work?

Receive News & Ratings for Medivir AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivir AB (publ) and related companies with's FREE daily email newsletter.